Clinical Utilities of Omega-3 Polyunsaturated Fatty Acids in ASCVD Risk Reduction

1.00 CME
1.00 AANP
$0 FEE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Clinical Utilities of Omega-3 Polyunsaturated Fatty Acids in ASCVD Risk Reduction


Provider Statement

This continuing education activity is provided by Vindico Medical Education

Support Statement

This activity is supported by an educational grant from Amarin Pharma, Inc.

Target Audience

The intended audience for this activity is family medicine physicians, internists, pharmacists, physician assistants, nurse practitioners, and other health care professionals involved in the management of patients at risk for cardiovascular events.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Incorporate understanding of anti-inflammatory mechanisms of omega-3 polyunsaturated fatty acids (PUFAs) in atherosclerotic cardiovascular disease (ASCVD) risk reduction.
  • Determine the pleiotropic benefits of omega-3 PUFAs and their clinical utilities in ASCVD.
  • Apply the most recent clinical evidence for impact of omega-3 PUFAs in CV outcomes trials, including interprofessional approaches to care for patients at risk for CV events.
  • Select statin-treated patients who are at risk for CV events despite well-controlled LDL-C levels and may benefit from ongoing pharmacological management for CV risk reduction.

Activity Chair

Director, Preventative Cardiology
CGH Medical Center
Sterling, IL
Professor, Clinical Family & Community Medicine
University of Illinois College of Medicine
Peoria, IL
Professor of Clinical Medicine
Michigan State University College of Osteopathic Medicine
East Lansing, MI
Adjunct Associate Professor Medicine
Johns Hopkins University School of Medicine
Baltimore, MD


Amit Khera, MD, MSc, FACC, FAHA, FASPC
Professor of Medicine
Director, Preventive Cardiology
UT Southwestern Medical Center
Dallas, TX

Pam R. Taub, MD, FACC, FASPC
Professor of Medicine
Director of Step Family Cardiac Rehabilitation and Wellness Center
Division of Cardiovascular Medicine
University of California San Diego
La Jolla, CA


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Jennifer Frederick, PharmD, BCPS
Linda A. Giarraputo, PA-C


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Vindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

abimSuccessful completion of this CME activity enables the participant to earn up to 1.00 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This program is acceptable for 1.00 contact hour of Accreditation Council for Pharmacy Education (ACPE) Continuing Education Credit. The ACPE Universal Program Number is 0482-0000-22-016-H01-P, effective 6/20/2022. This is a knowledge-based activity and there is no fee to attend.

aanpThis activity is approved for 1.0 contact hour(s) of continuing education (which includes 0.67 hour(s) of pharmacology) by the American Association of Nurse Practitioners®. Activity ID# 22065589. This activity was planned in accordance with AANP Accreditation Standards and Policies.

aapaThis activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 1AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation. Approval is valid from 6/20/2022 to 6/19/2023. AAPA reference number: CME-206329.

This enduring material is approved for 1 year from the date of original release, June 20, 2022, to June 19, 2023.

How to Participate in This Activity and Obtain CE Credit

To participate in this CE activity, you must read the learning objectives, answer the polling and pretest questions, listen to the podcasts, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate, AAPA Category 1 CME Certificate, AANP Contact Hour Certificate, or Statement of Continuing Pharmacy Education Credit.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 30 days.


Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Activity Chair and Faculty report the following relationship(s)

Amit Khera, MD, MSc, FACC, FAHA, FASPC
No relevant financial relationships to disclose.

Pam R. Taub, MD, FACC, FASPC
Consultant: Amarin, Amgen, Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, Sanofi

Consultant: Amarin, AstraZeneca, Kowa, Merck, Novartis, Resverlogix, Theravance
Speaker Contracted by Ineligible Company: Amarin, Amgen, Esperion, Novartis, Novo Nordisk

Planners/Reviewers report the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP; Jennifer Frederick, PharmD, BCPS; and Linda A. Giarraputo, PA-C
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

ADA Disclaimer

In compliance with the Americans with Disabilities Act of 1990, we will make all reasonable efforts to accommodate persons with disabilities. A text-based transcript of this Podcast is available upon request. Requests should include the Podcast title and can be emailed to Requests will be honored within 3-5 business days.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2022 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CE Questions?

Contact us at